Growth of Ulcerative Colitis Market Value Projected to Amplify During 2017-2022

Ulcerative Colitis Market Value Information, by type (Ulcerative Proctitis, Proctosigmoiditis, Left-Sided Colitis, Pancolitis or Universal Colitis, and Fulminant Colitis), by Medication (5-Aminosalicylates, Steroids, Purine Analogs, Immunomodulators, and Biologics) – Forecast to 2022

Market Research Future published a Half-Cooked research report on “Global Ulcerative Colitis Market Value Research Report – Forecast till 2022” – Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2022.

 

Global Ulcerative Colitis Market Value – Overview

The market for ulcerative colitis is growing due to increasing demand for biologics for treating bowel disorders such as ulcerative collates and is propelling the overall market growth of global ulcerative market. Higher inclination for symptomatic therapeutic and drugs over surgeries, increase in patient assistance programs, better treatment and management of inflammatory bowel diseases, the arrival of advanced drugs in the market owing to healthier investments in R&D programs are some of the key trends governing the market. Moreover, drug manufacturers are actively focusing on advanced products having higher efficiency. The growing patient population is an additional factor anticipated to influence the market growth between 2016 and 2022. Also the increase in patient assistance programs is a major driver of the market. The provision of these programs by vendors will upsurge the preference for branded drugs because the out-of-pocket burdens would be less as the drugs are obtained at lower costs.

Global Ulcerative Colitis Market Value   – Regional Analysis

The market of ulcerative colitis is much higher in the Americas region. In Americas, North America commands the largest market share of global Ulcerative Colitis Market Value and is expected to grow at the same pace. Asia Pacific shows sufficient cases recoded for the disease due to lack of infrastructure and awareness and is expected to be the fastest growing segment with the highest CAGR due to continuous improvement in healthcare sector and increasing awareness among people. According to the US Center for Disease Control, there is an ulcerative colitis prevalence of 238 per 100,000 adults. The number of ulcerative colitis patients is increasing in emerging economies as per the development in technology, these developing or emerging economies are expected to account for the larger market share in coming future.

 

 

Allergan, Inc., AbbVie Inc., Takeda Pharmaceutical Company Limited, Bayer AG, UCB S.A., Perrigo Company plc, Pfizer Inc., Johnson & Johnson Services, Inc., Ferring B.V., Janssen Biotech, and Merck are some of the leading players at the cutting edge of the competition in the market of ulcerative Colitis, globally.

Browse Complete Report :https://www.marketresearchfuture.com/reports/ulcerative-colitis-market-2354

Key developments

Companies are continuously developing new products to capture the market globally. Thus major players invest more in research and development activity, in order to lead the global market. In this regards, market players undertake various strategic approaches.

Johnson & Johnson Services Inc.

September, 2016: Acclarent Inc., a subsidiary of Johnson & Johnson, received FDA approval for ACCLARENT AERA Eustachian Tube Balloon Dilation System. It is a first FDA-approved device to treat Eustachian Tube Dysfunction effectively.

March, 2016: Ethicon, a medical device company of the Johnson & Johnson, acquired NeuWave Medical, Inc.

June, 2015: Verb Surgical Company was created by the collaboration of Ethicon and Verily.

March, 2015: Ethicon, a medical device company of the Johnson & Johnson, enter into a collaboration with Google, Inc.

Pfizer Inc.

Pfizer Inc. is a leading research based bio pharmaceutical organization. Pfizer apply science and our worldwide assets to convey inventive treatments that develop and essentially enhance lives. Pfizer makes medicines and vaccines that help individuals when they are sick and keep them from becoming sick in any case, and additionally a portion of some of the world’s best-known consumer healthcare brands.

August, 2016: FDA approves Pfizer’s TROXYCA ER extended-release capsules CII for pain management. This drug is used for abuse-deterrent properties for the management of pain and will help Pfizer to improve their goodwill and sales with this new product

July 2016: Bind Therapeutics entered into an asset purchase agreement with Pfizer Inc. Bind Therapeutics Inc. entered into an asset purchase agreement with Pfizer, Inc. On July 26, 2016, company amended the stalking horse agreement. The acquisition is expected to close on or about August 1, 2016.

July 2016: Pfizer and Western Oncolytics announce immuno-oncology research collaboration. This collaboration has the aim to investigate novel oncolytic virus technology. Under terms of agreement, Pfizer and Western Oncolytics will collaborate on preclinical, clinical development of WO-12 through Phase I trials. Financial terms of agreement are not disclosed

June 2016: Pfizer completed the acquisition of Anacor Pharmaceuticals. This acquisition has a motive for Pfizer, so that the company can accelerate their shared commitment to help patients with inflammatory disease, an area of high unmet medical need

Merck:

January, 2017: Merck Acquired BioControl to Strengthen Position in Food Safety Testing

August, 2012: Merck Acquired Cell Culture Media Specialist Biochrom AG 

Allergan

November, 2017- Allergan plc company announced its data will be presented at the annual American Academy of Ophthalmology (AAO) meeting in New Orleans, Louisiana, U.S. Allergan has a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women’s health, urology and anti-infective therapeutic categories. The company is an industry leader in Open Science, a model of research and development, which defines company’s approach to identifying and developing ideas and innovation for better patient care.

August, 2016- Allergan acquired eye care company ForSight VISION5 which added peri-ocular ring technology to Company’s leading portfolio of innovative eye health products. Allergan has been a leader in the development and introduction of novel treatments for underserved eye conditions, including glaucoma, chronic dry eye disease and other ocular conditions. According to company reports, this acquisition of this ring technology that has profoundly change the way patients receive treatment. The ring is a preservative-free, non-invasive peri-ocular product that rests on the surface of the eye .It is inserted by an Ophthalmologist or Optometrist, and releases medication (bimatoprost) over multiple months to lower elevated IOP in glaucoma and ocular hypertensive patients.